Physician profile
Buddima Ranasinghe
NPI 1417390162
$3,612.54
in general payments reported to CMS, 2019-2025
37 companies · $2,339 in 2025
The $2,339 reported for 2025 was more than what 83% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $295 · 2024: $979 · 2025: $2,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,580 · Travel and Lodging: $1,008 · Entertainment: $25.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,579.79 |
| Travel and Lodging | $1,007.66 |
| Entertainment | $25.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,356.99 | 2024-2025 | Aquabeam System |
| Boston Scientific Corporation | $581.09 | 2023-2025 | Moses 550 D\F\L, Lithovue, Spaceoar Vue System - 10ml |
| Convatec INC. | $151.75 | 2024 | |
| Abbvie INC. | $133.71 | 2024-2025 | |
| Urogen Pharma, INC. | $122.10 | 2024-2025 | |
| Calyxo, INC. | $101.15 | 2025 | Cvac Aspiration System |
| Sumitomo Pharma America, INC. | $88.45 | 2024-2025 | Gemtesa, Orgovyx |
| Coloplast Corp | $83.67 | 2024-2025 | |
| Axonics, INC. | $69.45 | 2024 | Bulkamid, Axonics |
| Immunitybio, INC. | $64.25 | 2025 | |
| Avation Medical, INC. | $59.30 | 2024-2025 | Vivally System, Vivally |
| Agiliti Surgical, INC. | $56.69 | 2025 | Sonablate Hifu |
| Ferring Pharmaceuticals INC. | $53.32 | 2025 | Adstiladrin |
| 180 Medical, INC. | $47.82 | 2023-2024 | Cure Catheter |
| Bluewind Medical | $46.14 | 2025 | Revi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $43.77 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Pfizer INC. | $41.62 | 2024 | |
| Civco Medical Instruments | $40.69 | 2023-2024 | |
| Progenics Pharmaceuticals, INC. | $38.89 | 2025 | |
| Laborie Medical Technologies Corp. | $38.52 | 2025 | |
| Ethicon US, LLC | $36.97 | 2024 | Stratafix |
| Merck Sharp & Dohme LLC | $34.31 | 2024 | Lynparza |
| C. R. Bard, INC. & Subsidiaries | $31.78 | 2024 | Bard Urinary Drainage Bag |
| Steris Corporation | $29.02 | 2025 | |
| Smith+Nephew, INC. | $28.54 | 2025 | Grafix Pl |
| Blue Earth Diagnostics | $27.79 | 2024 | |
| Medtronic, INC. | $27.33 | 2024 | Interstim |
| Dendreon Pharmaceuticals LLC | $26.34 | 2024 | Provenge |
| Provepharm INC. | $25.09 | 2023 | Bludigo |
| Telix Pharmaceuticals | $24.21 | 2025 | Illuccix |
| Ambu INC. | $21.93 | 2023 | |
| Tolmar, INC. | $19.59 | 2025 | Jatenzo, Eligard |
| Cycle Pharmaceuticals INC | $17.65 | 2025 | Venxxiva |
| Valencia Technologies Corporation | $17.46 | 2025 | Ecoin Device Kit |
| Avanos Medical | $16.60 | 2024 | On-Q* Pump and Accessories |
| Mission Pharmacal Company | $8.56 | 2024 | Uribel Tabs |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$41,236.42 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Buddima Ranasinghe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.